Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified

Screening

Active

18 and over

Other

06-122
NCT00601146

Trial Description

Summary

This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

Further Study Information

Participants will undergo a chest computed tomography (CT) scan once a year for a 3-year period.

Eligibility Criteria

Inclusion Criteria:

5 years or longer from initial Hodgkin's disease diagnosis

Current age 18 or older

Received mediastinal irradiation and/or alkylating-agent based chemotherapy

Smoking history of 10-pack years or more, or current smoker

Pre-approval from the participant's insurance company for the CT study

Exclusion Criteria:

Patients with a history of lung cancer

Currently receiving treatment for another cancer diagnosis

Known diagnosis of any metastatic cancer

Pregnant women

Trial Contact Information

Trial Lead Organizations/Sponsors

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Dana-Farber/Brigham and Women's Cancer Center

Andrea K. Ng, MD

Principal Investigator

Andrea K. Ng,, MD

Ph: 617-732-7361

Trial Sites

U.S.A.

Massachusetts

Boston

Dana-Farber/Brigham and Women's Cancer Center

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00601146
Information obtained from ClinicalTrials.gov on January 07, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.